Navigation path



Published: 23 January 2014  
Related category(ies):
Health & life sciences  |  Special Collections  |  Research policy


Countries involved in the project described in the article:
Belgium  |  Germany  |  Sweden  |  United Kingdom
Add to PDF "basket"

Ground-breaking cancer research

Cancer treatment is one of the most important areas of research in the medical world today. With research predominately conducted in large pharmaceutical research organisations, it is a positive sign when smaller players take up the challenge to develop their own innovative treatment for cancer.

© fotolia

Under the ANGIOSTOP project, with EU-funding of nearly EUR 2 million, two small research-based pharmaceutical companies – Sweden’s BioInvent (the primary coordinator) and Thrombogenics in Belgium – have joined forces with three other partners to create a new synergy between academic groups and small and medium-sized enterprises (SMEs). Their aim was to generate a more focused and streamlined strategy for cancer treatment development, avoiding the bureaucratic decision-making which sometimes handicaps large networks and pharmaceuticals.

The project looked at the novel anti-angiogenic treatment for cancer, arthritis and ocular neovascularisation based on the inhibition of placental growth factor (PlGF). The idea was to seek innovative forms of treatment that could stop the growth of cancerous tumours through the inhibition of angiogenesis – the process by which new blood vessels are formed in the body.

It was crucial to develop a safer and more effective anti-angiogenic medicine that reduces the pathological blood vessel formation associated with cancer and other diseases.

The ANGIOSTOP project succeeded in developing a potentially important new treatment, by studying an antibody that specifically targets PIGF. A detailed programme was drawn up outlining how the research team would develop this antibody for clinical use.

Now, following three years of research, the antibody treatment has been shown to have a significant effect on tumour models in mice. A subsequent toxicology study revealed the treatment to be safe for human use which means further clinical studies can now be undertaken.

The breakthrough findings have gained the attention of Roche, a global pharmaceutical maker, which has now injected EUR 50 million into the endeavour. ANGIOSTOP partners say this amount could be increased to EUR 450 million, if the project reaches certain development milestones.

Overall, the project has paved the way for clinical development with the lead candidate anti-PlGF antibody, as set out in the objectives. Coupled with better understanding of pathologic angiogenesis and new models and strategies, this could prove useful for developing new medicines aimed at increasing or reducing blood vessel formation, the researchers conclude.


Project details

  • Project acronym: ANGIOSTOP
  • Participants: Sweden (Coordinator), United Kingdom, Belgium, Germany
  • Project FP6 37386
  • Total costs: € 5 146 847
  • EU contribution: € 1 993 208
  • Duration: June 2006 - May 2009

Convert article(s) to PDF

No article selected


Search articles

To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site
Project information on CORDIS

  Top   Research Information Center